Skip to content

A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety

A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safety - A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole: A randomized controlled trial(JPIGANTS01)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000363
Enrollment
80
Registered
2007-05-14
Start date
2001-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy in children

Interventions

prednisolone+mizoribine for 2 years prednisolone+mizoribine+warfarin+dipyridamole for 2 years

Sponsors

The Japanese Pediatric IgA Nephropathy of Treatment Study Group
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Newly biopsy proven IgA nephropathy with diffuse mesangial proliferation 2.Aged 2 to 18 years 3.Written informed consent from the patients' parents or legal guardians

Exclusion criteria

Exclusion criteria: 1.Systemic diseases defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus, etc) 2.Medical history of allergy or hypersensitivity reactions to prednisolone, mizoribine, warfarin or dipyridamole 3.Chronic renal dysfunction 4.Active infectious disease 5.Severe liver disfunction 6.History of corticosteroid and immunosupressive drug use 7.Pregnancy 8.Judged inappropriate for this study by the physicians

Design outcomes

Primary

MeasureTime frame
Disappearance rate of proteinuria

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026